J.P. Morgan analyst Jessica Fye has maintained their neutral stance on INCY stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jessica Fye’s rating is based on a combination of factors related to Incyte’s current clinical developments and market position. The early clinical data for Incyte’s KRAS G12D inhibitor in pancreatic cancer shows promise, but the data is still immature, and more comprehensive results expected in the first half of 2026 will be crucial to understanding its competitive edge. The safety profile appears acceptable for combination with chemotherapy, which is a key focus for its development, but the competition in second-line pancreatic cancer is perceived to be too advanced for Incyte to pursue monotherapy at this time.
Additionally, the investor interest in Incyte’s TGFβR2×PD-1 bispecific antibody has been limited, despite showing some single-agent activity in microsatellite stable colorectal cancer patients. While this represents progress, the overall response rates are not particularly high. Incyte is in a period rich with potential catalysts, and the upcoming data on the mCALR antibody could significantly impact the stock’s outlook. However, the uncertainty surrounding these developments and the pressure on upcoming readouts contribute to the Hold rating, as the long-term revenue potential remains to be fully defined.
Fye covers the Healthcare sector, focusing on stocks such as Insmed, Ionis Pharmaceuticals, and Alnylam Pharma. According to TipRanks, Fye has an average return of 9.4% and a 55.46% success rate on recommended stocks.